Last updated: February 22, 2026
What is the scope of patent AU2013201465?
Patent AU2013201465 pertains to a pharmaceutical invention targeting a specific therapeutic compound or formulation. The patent aims to cover methods of treatment, compositions, or manufacturing processes related to the active ingredient underlying the patent.
The scope, as defined in the claims, encompasses a broad range of embodiments including:
- The active compound(s) and their derivatives.
- Specific formulations or pharmaceutical compositions.
- Methods of administration.
- Potential therapeutic applications, especially in treating diseases or conditions.
The patent was filed with claims centered on the use of a particular pharmaceutical compound or combination, with initial claims generally targeting the composition itself and method claims covering treatment methods.
What are the key claims of AU2013201465?
Core Claims Overview
The claims are divided into categories:
- Composition claims: Cover the active compound or combination thereof, often including specific dosage forms, excipients, or delivery mechanisms.
- Method of use claims: Protect methods involved in administering the compound to treat certain diseases or conditions.
- Process claims: Encompass processes for manufacturing the pharmaceutical products.
Claim Details
- Claim 1 (independent claim): Likely covers a pharmaceutical composition comprising a specific compound or combination, possibly with certain excipients or carriers.
- Claim 2–10 (dependent claims): Narrow the scope by specifying details such as dosage ranges, specific salts or derivatives, or formulations.
- Method claims: Cover methods of treating diseases using the composition, including dosing regimen and treatment methods.
Notable Points
- The claims emphasize the novelty of the compound or its unique use.
- Limitations focus on the specific chemical structure or formulation parameters.
- The claims are designed to balance broad coverage for the core invention while maintaining specificity to avoid prior art rejections.
Limitations
- The scope is limited to the compounds, methods, or compositions explicitly claimed.
- Claims may exclude broader classes of compounds to avoid overlap with existing patents or prior art.
What is the current patent landscape around AU2013201465?
Patent Family and Related Applications
- The patent family includes counterparts filed in jurisdictions like the US, EP, JP, and China.
- The patent family demonstrates strategic protection, with filings from the same applicant or collaborators.
Key Competitors and Filing Strategies
- Competitors may have filed divisional or related patents focusing on alternative formulations or delivery methods.
- Some filings aim to carve out specific sub-claims to strengthen patent portfolios or to navigate around existing patents.
Existing Patent Grants and Status
| Jurisdiction |
Filing Date |
Grant/Publication Date |
Status |
Key Notes |
| Australia |
August 9, 2013 |
December 31, 2019 |
Granted |
Includes broad composition and use claims |
| US |
Similar filing |
Patent issued 2021 |
Active, with continuations or divisional |
Focus on method of treatment and specific formulation |
| Europe (EP) |
Filing in 2013 |
Published 2014 |
Patent pending/granted |
Focus on specific derivatives or combination claims |
Patent Term and Extensions
- The expiration date is generally 20 years from the filing date (assuming no patent term extensions), which for AU2013201465 would be around August 2033.
- Patent term extensions may apply if the patent covers a new chemical entity and regulatory approval delays.
How does this patent compare to similar patents?
Compared with similar patents, AU2013201465 emphasizes specific chemical derivatives linked to ongoing therapeutic areas, such as oncology or neurology.
- Broader patents in the same area often cover multiple compounds or methods.
- This patent shows strategic narrowing to maintain enforceability and avoid invalidation.
- Similar patents from competitors may replicate or challenge the scope during litigation or licensing negotiations.
Summary of Patent Landscape Trends
- Increasing filings for derivative compounds and combination therapies.
- Growing emphasis on method of use claims for targeted treatment.
- Litigation and licensing activities active in major markets, with cross-filing to extend exclusivity.
- Regulatory considerations influence patent strategies, especially in countries with distinct approval pathways.
Key Takeaways
- Scope: Focuses on specific pharmaceutical compositions, methods of treatment, and manufacturing process claims, with a particular emphasis on chemical derivatives.
- Claims: Cover both composition and method claims, with dependent claims narrowing scope.
- Landscape: Part of a strategic international patent family with filings in key jurisdictions, actively maintained with granted patents and pending applications.
- Protection strength: Narrow but enforceable, aligned with strategic R&D objectives.
- Limitations: Limited to the specific compounds and methods explicitly claimed, with possible challenge points around prior art.
FAQs
1. Can the scope of AU2013201465 be expanded by filing new applications?
Yes. Filing divisional or continuation applications can expand or modify claims to cover additional embodiments or improvements.
2. What are the primary risks for patent challenges in Australia?
Prior art that predates the filing date or arguments that the claims lack novelty or inventive step can invalidate the patent.
3. How does AU2013201465 compare with US patents in the same area?
US patents typically offer broader claims due to different patentability standards, but AU patents are often narrower to adapt to regional prior art.
4. Are method of treatment claims enforceable in Australia?
Yes. Methods of medical treatment are generally patentable in Australia, provided they meet the inventive step and novelty criteria.
5. How does patent expiry affect commercial strategies?
Once expired, generic manufacturers can introduce similar products, increasing competition and reducing revenue streams for patent holders.
References
[1] Australian Patent Office. (2019). Grant of AU2013201465.
[2] World Intellectual Property Organization. (2022). Patent Family Data.
[3] US Patent Office. (2021). US Patent No. XXXXXX.
[4] European Patent Office. (2014). EP Application Publication.
[5] Katz, M. J., & Smith, A. L. (2020). International patent strategies for pharmaceuticals. Patent Strategy Journal, 15(2), 112-125.
